Advertisement
U.S. markets closed

Marinus Pharmaceuticals, Inc. (MRNS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
9.75+0.21 (+2.20%)
At close: 04:00PM EST
9.58 -0.17 (-1.74%)
After hours: 05:20PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Bollinger Bands

Bollinger Bands

Previous Close9.54
Open9.54
Bid9.31 x 900
Ask10.11 x 800
Day's Range9.44 - 9.78
52 Week Range5.57 - 11.26
Volume201,012
Avg. Volume398,085
Market Cap532.093M
Beta (5Y Monthly)0.95
PE Ratio (TTM)N/A
EPS (TTM)-2.78
Earnings DateMar 05, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.30
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for MRNS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Marinus Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 11/16/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • Business Wire

    Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

    RADNOR, Pa., February 21, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present at and participate in the following conferences in March.

  • Business Wire

    Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024

    RADNOR, Pa., February 20, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 on March 5, 2024. The Company will host a conference call at 4:30 p.m. E.T. on March 5, 2024, to provide a business update and discuss financial results.

  • Business Wire

    Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    RADNOR, Pa., February 16, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to four new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 64,425 shares of its common stock (the "Common Stock") as inducements material to the employees enter